Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

Abstract Background Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case We present...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2008-12, Vol.111 (3), p.530-532
Main Authors: Hamilton, Chad A, Maxwell, G. Larry, Chernofsky, Mildred R, Bernstein, Sarah A, Farley, John H, Rose, G. Scott
Format: Article
Language:English
Subjects:
Aged, 80 and over
Angiogenesis Inhibitors - administration & dosage
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Ascites
Ascites - drug therapy
Ascites - pathology
Ascites - surgery
Bevacizumab
Female
Hematology, Oncology and Palliative Medicine
Humans
Infusions, Parenteral
Intraperitoneal
Obstetrics and Gynecology
Ovarian cancer
Ovarian Neoplasms - blood supply
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Ovarian Neoplasms - surgery
Palliation
Palliative Care - methods
Paracentesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion Intraperitoneal bevacizumab may be a useful tool in the palliation of malignant ascites and is worthy of further study.
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2008.04.028